Skip to content
AnalystLens

Merck Annual Report (Amendment), Year Ended Dec 31, 2007

Filing Date
Filed March 3, 2008
Period End
December 31, 2007
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K/A filed March 3, 2008. Cited figures are marked; the original filing is the authoritative source.

Schering-Plough reported consolidated net sales of $12.7 billiona for the year ended December 31, 2007, a 20% increase over the prior year, largely driven by the acquisition of Organon BioSciences N.V.

(OBS) and growth in key pharmaceutical products like REMICADE, TEMODAR, and NASONEX. However, the company incurred a net loss of $1.6 billionb, primarily due to significant purchase accounting charges, including $3.8 billion for acquired in-process research and development related to the OBS acquisition. The company's cholesterol franchise, managed through a joint venture with Merck, continued to show strong sales growth in 2007, though early 2008 saw negative media scrutiny and prescription declines for VYTORIN and ZETIA following the release of ENHANCE clinical trial results, leading to investigations and litigation.

Schering-Plough's R&D spending increased significantly, reflecting investments in its pipeline and the OBS acquisition, with continued expected increases to support late-stage development. Investors should note the substantial impact of the OBS acquisition on both sales and reported losses, the ongoing legal and regulatory scrutiny surrounding the cholesterol joint venture products, and the company's reliance on key products like REMICADE and the joint venture products for future profitability.

The company's financial position was strengthened by significant debt and equity issuance to finance the OBS acquisition. Despite the net loss in 2007, operating cash flow remained positive.

Key Highlights

  1. Consolidated net sales increased 20% to $12.7 billion in 2007, driven by the acquisition of Organon BioSciences N.V. (OBS) and growth in key products.
  2. The company reported a net loss of $1.6 billion in 2007, largely due to $3.8 billion in acquired in-process R&D charges from the OBS acquisition.
  3. The Merck/Schering-Plough cholesterol joint venture (VYTORIN and ZETIA) experienced strong sales growth in 2007, contributing significantly to overall results.
  4. Early 2008 saw negative publicity and prescription declines for VYTORIN and ZETIA due to the ENHANCE trial results, leading to investigations and litigation.
  5. Research and development expenses rose 34% to $2.9 billion in 2007, reflecting increased investment in the product pipeline and the OBS acquisition.
  6. Schering-Plough strengthened its financial position by issuing significant debt and equity to fund the OBS acquisition, which closed in November 2007.
  7. Key products like REMICADE, NASONEX, TEMODAR, and CLARINEX continued to show strong sales performance across various therapeutic areas.

Frequently Asked Questions

  1. What was the financial performance of Schering-Plough in 2007?

    In 2007, Schering-Plough reported a 20% increase in consolidated net sales to $12.7 billion, primarily driven by the acquisition of Organon BioSciences N.V. (OBS) and growth in key pharmaceutical products. However, the company recorded a net loss of $1.6 billion, significantly impacted by $3.8 billion in acquired in-process R&D charges and other purchase accounting adjustments related to the OBS acquisition.

  2. What is the status of the Merck/Schering-Plough cholesterol joint venture (VYTORIN and ZETIA)?

    The joint venture's cholesterol products, VYTORIN and ZETIA, showed strong sales growth in 2007. However, early in 2008, the ENHANCE clinical trial results generated significant negative media attention and led to prescription declines. This has resulted in multiple investigations by Congress and state officials, as well as class-action lawsuits against the company.

  3. How did the acquisition of Organon BioSciences N.V. (OBS) impact Schering-Plough's financials?

    The acquisition of OBS, completed in November 2007, significantly boosted net sales by $626 million and added new therapeutic areas and animal health capabilities. However, it also resulted in substantial purchase accounting charges, including $3.8 billion for acquired in-process R&D and $1.1 billion for acquired inventory, leading to a significant net loss for the year. The acquisition also led to a large increase in goodwill and other intangible assets on the balance sheet.

  4. What are the company's key growth drivers and R&D focus?

    Key growth drivers include the cholesterol franchise (VYTORIN/ZETIA), REMICADE, NASONEX, TEMODAR, and CLARINEX. Schering-Plough's R&D efforts are concentrated on six therapeutic areas: Cardiovascular, Central Nervous System, Immunology and Infectious Disease, Oncology, Respiratory, and Women’s Health. R&D spending increased significantly in 2007, and the company anticipates continued increases to support its expanding product pipeline, including late-stage projects.